Tranexamic acid-an alternative to aprotinin in fibrin-based cardiovascular tissue engineering

Tissue Engineering - Part A

Volumn 15, Issue 11, 2009, Pages 3645-3653

  Cholewinski, Eva ^a   Dietrich, Maren ^a   Flanagan, Thomas C ^b   Schmitz Rode, Thomas ^a   Jockenhoevel, Stefan ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIODEGRADATION; CARBOXYLIC ACIDS; CELL CULTURE; DEGRADATION; GELS; LIGHT TRANSMISSION; MECHANICAL STABILITY; ORGANIC ACIDS; SCANNING ELECTRON MICROSCOPY; SYNCHROTRONS; THREE DIMENSIONAL; TISSUE; TRANSMISSION ELECTRON MICROSCOPY;

APROTININ; CARDIOVASCULAR TISSUE ENGINEERING; CAROTID ARTERY; CELL MORPHOLOGY; CLINICAL APPLICATION; CLINICAL TRIAL; CULTURE CONDITIONS; CULTURED CELL; CYTOTOXIC EFFECTS; FIBRIN GELS; FIBRIN-BASED SCAFFOLDS; IN-VITRO; LIGHT MICROSCOPY; MECHANICAL STRENGTH; NEGATIVE INFLUENCE; TISSUE DEVELOPMENT; TISSUE-ENGINEERED CONSTRUCTS; TRANEXAMIC ACID;

TISSUE ENGINEERING;

APROTININ; FIBRIN; TRANEXAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; FIBRINOLYSIS; HEART SURGERY; IN VITRO STUDY; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SHEEP; SPECTROPHOTOMETRY; TISSUE ENGINEERING; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR TISSUE;

EID: 72649092908     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2009.0235     Document Type: Article

References (38)

1. Flanagan, T.C., and Pandit, A.S. Living artificial heart valve alternatives: a review. Eur Cell Mater 6, 28, 2003.
2. Jockenhoevel, S., Chalabi, K., Sachweh, J.S., Groesdonk, H.V., Demircan, L., Grossmann, M., Zund, G., and Messmer, B.J. Tissue engineering: complete autologous valve conduit- a new moulding technique. Thorac Cardiovasc Surg 49, 287, 2001.
3. Flanagan, T.C., Cornelissen, C., Koch, S., Tschoeke, B., Sachweh, J.S., Schmitz-Rode, T., and Jockenhoevel, S. The in vitro development of autologous fibrin-based tissue-engineered heart valves through optimised dynamic conditioning. Biomaterials 28, 3388, 2007.
4. Ye, Q., Zund, G., Benedikt, P., Jockenhoevel, S., Hoerstrup, S.P., Sakyama, S., Hubbell, A.J., and Turina, M. Fibrin gel as a three dimensional matrix in cardiovascular tissue engineering. Eur J Cardiothorac Surg 17, 587, 2000.
5. Tschoeke, B., Flanagan, T.C., Cornelissen, A., Koch, S., Roehl, A., Sriharwoko, M., Sachweh, J.S., Gries, T., Schmitz-Rode, T., and Jockenhoevel, S. Development of a composite degradable/nondegradable tissue-engineered vascular graft. Artif Organs 32, 800, 2008.
6. Grassl, E.D., Oegema, T.R., and Tranquillo, R.T. A fibrin-based arterial media equivalent. J Biomed Mater Res 66, 550, 2003.
7. Aper, T., Teebken, O.E., Steinhoff, G., and Haverich, A. Use of a fibrin preparation in the engineering of a vascular graft model. Eur J Vasc Endovasc Surg 28, 296, 2004.
8. Williams, C., Johnson, S.L., Robinson, P.S., and Tranquillo, R.T. Cell sourcing and culture conditions for fibrin-based valve constructs. Tissue Eng 12, 1489, 2006.
9. Swartz, D.D., Russell, J.A., and Andreadis, S.T. Engineering of fibrin-based functional and implantable small-diameter blood vessels. Am J Physiol Heart Circ Physiol 288, H1451, 2005.
10. Haisch, A., Loch, A., David, J., Pruss, A., Hansen, R., and Sittinger, M. Preparation of a pure autologous biodegradable fibrin matrix for tissue engineering. Med Biol Eng Comput 38, 686, 2000.
11. Aper, T., Schmidt, A., Duchrow, M., and Bruch, H.P. Au-tologous blood vessel engineered from peripheral blood sample. Eur J Vasc Endovasc Surg 33, 33, 2007.
12. Fritz, H., and Wunderer, G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 3, 479, 1983.
13. Alston, T.A. Aprotinin. Int Anesthesiol Clin 42, 81, 2004.
14. Mangano, D.T., Tudor, I.C., and Dietzel, C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354, 353, 2006.
15. Mannucci, P.M. Hemostatic drugs. N Engl J Med 339, 245, 1998.
16. Smith, S.A., and Morrissey, J.H. Polyphosphate enhances fibrin clot structure. Blood 112, 2598, 2008.
17. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55, 1983.
18. Jockenhoevel, S., Zund, G., Hoerstrup, S.P., Chalabi, K., Sachweh, J.S., Demircan, L., Messmer, B.-J., and Turina, M. Fibrin gel-advantages of a new scaffold in cardiovascular tissue engineering. Eur J Cardiothorac Surg 19, 424, 2001.
19. Wozniak, G. Fibrin sealants in supporting surgical techniques: the importance of individual components. Cardio-vasc Surg 11 (Suppl 1), 17, 2003.
20. Fussenegger, M., Meinhart, J., Höbling, W., Kullich, W., Funk, S., and Bernatzky, G. Stabilized autologous fibrin-chondrocyte constructs for cartilage repair in vivo. Ann Plast Surg 51, 493, 2003.
21. Meinhart, J., Fussenegger, M., and Hö bling, W. Stabilization of fibrin-chondrocyte constructs for cartilage reconstruction. Ann Plast Surg 42, 673, 1999.
22. Ting, V., Sims, C.D., Brecht, L.E., McCarthy, J.G., Kasabian, A.K., Connelly, P.R., Elisseeff, J., Gittes, G.K., and Longaker, M.T. In vitro prefabrication of human cartilage shapes using fibrin glue and human chondrocytes. Ann Plast Surg 40, 413, 1998.
23. Bedirhan, M.A., Turna, A., Yagan, N., and Tasci, O. Aprotinin reduces postoperative bleeding and the need for blood products in thoracic surgery: results of a randomized double-blind study. Eur J Cardiothorac Surg 20, 1122, 2001.
24. Bidstrup, B.P., Royston, D., Sapsford, R.N., and Taylor, K.M. Reduction in blood loss and blood use after cardiopulmo-nary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97, 364, 1989.
25. Boylan, J.F., Klinck, J.R., Sandler, A.N., Arellano, R., Greig, P.D., Nierenberg, H., Roger, S.L., and Glynn, M.F. Tra-nexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 85, 1043, 1996.
26. Brown, R.S., Thwaites, B.K., and Mongan, P.D. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial. Anesth Analg 85, 963, 1997.
27. Casati, V., Guzzon, D., Oppizzi, M., Bellotti, F., Franco, A., Gerli, C., Cossolini, M., Torri, G., Calori, G., Benussi, S., and Alfieri, O. Tranexamic acid compared with high-dose apro-tinin in primary elective heart operations: effects on perio-perative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 120, 520, 2000.
28. Westaby, S. Aprotinin in perspective. Ann Thorac Surg 55, 1033, 1993.
29. Fergusson, D.A., Hebert, P.C., Mazer, C.D., Fremes, S., MacAdams, C., Murkin, J.M., Teoh, K., Duke, P.C., Arellano, R., Blajchman, M.A., Bussières, J.S., Côté, D., Karski, J., Marti-neau, R., Robblee, J.A., Rodger, M., Wells, G., Clinch, J., and Pretorius, R. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358, 2319, 2008.
30. Mahdy, A.M., and Webster, N.R. Perioperative systemic haemostatic agents. Br J Anaesth 93, 842, 2004.
31. Pipan, C.M., Glasheen, W.P, Matthew, T.L., Gonias, S.L., Hwang, L.J., and Spontnitz, W.D. Effects of antifibrinolytic agents on the life span of fibrin sealant. J Surg Res 53, 402, 1992.
32. Vankemmel, O., de La Taille, A., Burnouf, T., Rigot, J.M., Duchene, F., and Mazeman, E. Evaluation of a fibrin sealant free of bovine-derived components in an experimental vas anastomosis study. Urol Int 65, 196, 2000.
33. Furtmüller, R., Schlag, M.G., Berger, M., Hopf, R., Huck, S., Sieghart, W., and Redl, H. Tranexamic acid, awidelyusedanti-fibrinolytic agent, causes convulsions by a y-aminobutyric acid receptor antagonistic effect. J Pharmacol Exp Ther 301, 168, 2002.
34. Schlag, M.G., Hopf, R., and Redl, H. Convulsive seizures following subdural application of fibrin sealant containing tranexamic acid in a rat model. Neurosurgery 47, 1463, 2000.
35. Cox, S., Cole, M., Mankarious, S., and Tawil, N. Effect of tranexamic acid incorporated in fibrin sealant clots on the cell behavior of neuronal and nonneuronal cells. J Neurosci Res 72, 734, 2003.
36. Furst, W., Banerjee, A., and Redl, H. Comparison of structure, strength and cytocompatibility of a fibrin matrix supplemented either with tranexamic acid or aprotinin. J Biomed Mater Res B Appl Biomater 82, 109, 2006.
37. Asted, B. Clinical pharmacology of tranexamic acid. Scand. J Gastroenterol 137, 22, 1987.
38. Flanagan, T.C., Sachweh, J.S., Frese, J., Schnoering, H., Gronloh, N., Koch, S., Tolba, R., Schmitz-Rode, T., and Jockenhoevel, S. In vivo remodelling and structural characterisation of fibrin-based tissue-engineered heart valves in the adult sheep model. Tissue Eng Part A. 2009 Mar 25. [Epub ahead of print]